Nectar Lifesciences (NECLIFE) is loss-making over the last 12 months, losing ₹73 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹10.05, 55% below its 52-week high. It is a small-cap company with a market cap of ₹195 Cr, ranked 96th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 27% over the past year.
- ₹10.25
- ₹10.25
- ₹9.98
- ₹10.20
- 1.1 L
Health check
- ReturnsBehind
−27.2% over a year, better than 0 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- Growthn/a
Not enough yearly results to measure.
- ProfitabilityNegative
ROCE -14.8% vs peer median 17.9%.
- Balance sheetn/a
Balance sheet figures aren’t reported.
- Red flags5 to check
Loss-making over the last twelve months.
Small cap
Defensive
Key metrics
- Market cap
- ₹195 Cr
- Small cap
- P/E
- 28.7
- Industry 28.7
- Price to book
- 0.35
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- −38.1%
- Peers 14.7%
- ROCE
- −14.8%
- Peers 17.9%
- Debt to equity
- n/a
- Debt ₹0.00 Cr
- EPS (TTM)
- ₹0.35
- Face value ₹1
- OPM (TTM)
- −168707.6%
- Net margin 0.0%
- Sales growth
- −100.0%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 13464.30
- EV/EBITDA −1.1
Strengths and risks
Strengths
- Promoter stake up from 44.9% to 51.8%.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −38.1%.
- Quarterly sales down 100.0% on a year ago.
- 55% below its 52-week high.
- Interest coverage of only −42.9×.
About Nectar Lifesciences
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin…
- Headquarters
- Chandigarh
- Employees
- 111
- Sector
- Healthcare
- ISIN
- INE023H01027
- Website
- neclife.com
Price range
- Avg volume (3M)
- 2.1 L
- 1-year return
- minus 27.2%
- From 52-week high
- minus 55.1%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| NECLIFENectar Lifesciences | 10.05 | minus 1.47% | 195 | 28.7 | 0.35 | −14.8% | −38.1% | −168707.6% | – | – | 0.00% | minus 27.2% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| – | 5 | – | – | 0 | |
| – | 5.3 | – | – | 27.3 | |
| −0.1 | −0.3 | −1.9 | −57.2 | −27.3 | |
| – | −6.6% | – | – | −188082.1% | |
| 0.3 | 0 | 0.7 | 6.3 | 2.9 | |
| 0 | – | 30.2 | 5.9 | 0.2 | |
| 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | |
| – | – | 88.2 | – | – | |
| 0.1 | −0.5 | 56.6 | −56.9 | −24.6 | |
| 34.9% | 34.9% | −19.5% | 34.6% | 36.2% | |
| −63.2 | −0.3 | 14.3 | −67.9 | −15.4 | |
| -2.82 | -7.85 | 0.64 | -3.38 | -0.79 |
Profit & loss
- ROE
- −38.1%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 1,524 | 1,684 | – | – | |
| 1,470 | 1,531 | – | – | |
| 53.9 | 153 | −0.2 | −6.3 | |
| 3.5% | 9.1% | – | – | |
| 5 | 14.9 | 63.2 | −6.5 | |
| 82.8 | 89.6 | – | 0.1 | |
| 59.1 | 60.7 | 62.4 | 22.8 | |
| 40.5 | 0.6 | 0.4 | −52.1 | |
| −42.4 | 18.3 | 1.1 | −87.9 | |
| 43.0% | 72.7% | 35.0% | 34.7% | |
| −24.2 | 5 | −114 | −293 | |
| -1.08 | 0.22 | -5.07 | -13.40 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 22.4 | 22.4 | 22.4 | 19.4 | |
| 1,042 | 1,047 | 934 | 563 | |
| 754 | 636 | 582 | – | |
| 371 | 486 | 509 | 39.3 | |
| 2,189 | 2,191 | 2,047 | 622 | |
| 690 | 656 | 633 | 103 | |
| 77.8 | 65.8 | 56.7 | – | |
| 0.2 | 0.2 | 0.2 | 3 | |
| 17.9 | 20.3 | 19.7 | 125 | |
| 1,403 | 1,449 | 1,337 | 390 | |
| 2,189 | 2,191 | 2,047 | 622 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 134 | 225 | 169 | −417 | |
| 51.7 | −17 | −41.9 | 1,205 | |
| −186 | −205 | −128 | −699 | |
| −0.2 | 2.2 | −0.6 | 88.9 | |
| −30.1 | −29.4 | −43.8 | −11.5 | |
| 104 | 195 | 126 | −429 |
Shareholding pattern
- Promoters51.84%
- Public48.16%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 51.84% | 48.16% | 0.00 | |
| 30 Jun 2026 | 51.84% | 48.16% | 0.00 | |
| 31 Mar 2026 | 51.84% | 48.16% | 0.00 | |
| 20 Jan 2026 | 51.84% | 48.16% | plus 6.93 | |
| 31 Dec 2025 | 44.91% | 55.09% | – |
Major shareholders
Filings & events
News
No recent news coverage found.